Over the past 2 decades, several incretin-based therapies, including GLP-1 receptor agonists (RAs) and dipeptidyl peptidase-4 (DPP-4) inhibitors, have been developed and approved for the treatment of both T2D and obesity. This evidence concerns the gene DPP4 and obesity due to melanocortin 4 receptor deficiency.